全文获取类型
收费全文 | 3574348篇 |
免费 | 296327篇 |
国内免费 | 14405篇 |
专业分类
耳鼻咽喉 | 48506篇 |
儿科学 | 113751篇 |
妇产科学 | 93383篇 |
基础医学 | 566673篇 |
口腔科学 | 94542篇 |
临床医学 | 323425篇 |
内科学 | 636596篇 |
皮肤病学 | 93956篇 |
神经病学 | 307341篇 |
特种医学 | 139488篇 |
外国民族医学 | 491篇 |
外科学 | 545728篇 |
综合类 | 108061篇 |
现状与发展 | 24篇 |
一般理论 | 2378篇 |
预防医学 | 301464篇 |
眼科学 | 81405篇 |
药学 | 244920篇 |
23篇 | |
中国医学 | 10734篇 |
肿瘤学 | 172191篇 |
出版年
2021年 | 55876篇 |
2020年 | 35563篇 |
2019年 | 58828篇 |
2018年 | 72435篇 |
2017年 | 55375篇 |
2016年 | 61323篇 |
2015年 | 75323篇 |
2014年 | 109762篇 |
2013年 | 175227篇 |
2012年 | 102859篇 |
2011年 | 103643篇 |
2010年 | 119575篇 |
2009年 | 123680篇 |
2008年 | 89731篇 |
2007年 | 93423篇 |
2006年 | 103681篇 |
2005年 | 98823篇 |
2004年 | 99967篇 |
2003年 | 90052篇 |
2002年 | 79390篇 |
2001年 | 118560篇 |
2000年 | 111989篇 |
1999年 | 107869篇 |
1998年 | 66832篇 |
1997年 | 64376篇 |
1996年 | 62202篇 |
1995年 | 57620篇 |
1994年 | 51548篇 |
1993年 | 48136篇 |
1992年 | 74339篇 |
1991年 | 69989篇 |
1990年 | 65713篇 |
1989年 | 64517篇 |
1988年 | 59471篇 |
1987年 | 58149篇 |
1986年 | 54689篇 |
1985年 | 54468篇 |
1984年 | 49546篇 |
1983年 | 45096篇 |
1982年 | 42207篇 |
1981年 | 39574篇 |
1980年 | 37262篇 |
1979年 | 40260篇 |
1978年 | 35592篇 |
1977年 | 32307篇 |
1976年 | 29638篇 |
1975年 | 27969篇 |
1974年 | 29037篇 |
1973年 | 28056篇 |
1972年 | 26265篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Prof. Dr. Alexander Kapp Prof. Dr. Bettina Wedi 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》2006,57(10):854-854
Ohne Zusammenfassung 相似文献
992.
993.
Vincent Chung Liang Liu Zhaoxiang Bian Zhongzhen Zhao Wai Leuk Fong Wan Fung Kum Jing Gao Min Li 《Movement disorders》2006,21(10):1709-1715
The objective of this study is to assess the efficacy and safety of herbal medicines (HMs), as a monotherapy or adjunct therapy, compared to placebo or conventional approaches in the treatment of idiopathic Parkinson's disease (PD). We conducted a systematic review of randomized controlled trials from both conventional and alternative medicine sources. Outcome measures were overall improvement, quality of life, reduction of levodopa dose, and adverse events. Nine studies were included, each testing a different HM. Six of the trials had limited internal validity due to major flaws in design, including the lack of proper randomization; insufficient blinding; unclear inclusive criteria in terms of diagnostic criteria, baseline staging, and duration of disease; lack of proper sample size calculation; and insufficient data analysis. Imbalances in gender and ethnicity among the patients in the included trials were observed. No major adverse events emerged, and no specific pattern was detected from the trials describing such data. In addition to major methodological defects, heterogeneity in (1) HM tested, (2) control treatment, and (3) outcome measure hindered in-depth data analysis and synthesis. Current evidence is insufficient to evaluate the efficacy and safety of various HMs. Further studies with improved trial design and reporting, with assessment on cost-effectiveness, quality of life, and qualitative data are warranted. 相似文献
994.
995.
996.
997.
Chest injuries can be sustained in isolation or in association with multiple injuries. Life-threatening complications may ensue because organs that are vital to survival of the organism are situated within the thoracic cavity. These complications include airway obstruction, tension pneumothorax, wide open pneumothorax, flail chest, cardiac tamponade and massive hemothorax. The mortality of patients hospitalized with chest injury can be as high as 10%. Clinical examination and awareness of the possibility of other injuries (high level of suspicion) are essential, and standard chest X-ray, ultrasound and thoracic computed tomography may also be needed for the diagnosis. The first part of this serial paper on the management of chest injuries focuses on anatomical aspects, pathophysiology and symptoms, but mainly on the indications for the standard diagnostic procedures and further high-tech examinations. 相似文献
998.
Kevin L Taylor Rhonda K Oates Ron Grane Douglas W Leaman Ernest C Borden Daniel J Lindner 《Journal of interferon & cytokine research》2006,26(5):353-361
Interferon-alpha (IFN-alpha) has proved effective in the treatment of hemangiomas, hemangioblastomas, and Kaposi's sarcoma. To investigate the ability of IFNs to inhibit angiosarcoma, we used two transformed murine endothelial cell lines that form angiosarcomas in vivo. SVR and MS1-VEGF cell lines express oncogenic H-ras or vascular endothelial growth factor (VEGF), respectively. IFN-alpha1,8, which is active against murine and human cells, inhibited SVR and MS1-VEGF proliferation in vitro by 40% at 10(3) U/mL (p = 0.028). In vivo, IFN-alpha1,8 inhibited SVR tumor volume by 71% (p = 0.047) and MS1-VEGF volume by 79% (p = 0.003). Tumor-induced angiogenesis was decreased in SVR tumors by 52% (p = 0.005) and in MS1-VEGF tumors by 58% (p = 0.001). Sera from IFN-alpha1,8-treated mice bearing either SVR or MS1-VEGF tumors demonstrated a 5-fold increase in IP-10/CXCL10 (p = 0.001), an IFN-induced antiangiogenic protein. Both recombinant IP-10 and IFN-alpha1,8 inhibited human umbilical vein endothelial cell (HUVEC) vessel formation in the fibrin gel assay, a three-dimensional culture model of angiogenesis, by 56% at 25 ng/mL and 50% at 1.2 ng/mL, respectively (p < 0.001). An IP-10 blocking antibody restored vessel formation to 80% of untreated controls (p = 0.001). Given the magnitude of the in vivo response, these data suggested that the antitumor effects of IFN-alpha1,8 were likely mediated through angiogenesis inhibition rather than solely by direct inhibition of tumor cell proliferation. 相似文献
999.
1000.
S. V. Terent’eva E. N. Komarova T. N. Sapozhnikova A. T. Teplyakov E. A. Ivanovskaya T. I. Andreeva 《Pharmaceutical Chemistry Journal》2006,40(12):694-696
A rapid procedure for determining angiotensin II in the blood by inverse voltammetry using a TA-2 device (Tekhnoanalit Company,
Tomsk) with a graphite electrode has been developed. The results of analyses using the proposed technique agree with the clinical
data. The rapid analytical procedure favors optimization of cardiotropic drug therapy.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 12, pp. 54–56, December, 2006. 相似文献